Jens Bukh

TL;DR: The data indicate that AR3A has a high barrier to resistance, and the approach permitted identification of low-level resistance substitutions, which suggest a complex role of HVR1 in virus escape and receptor usage in future HCV vaccine development.

TL;DR: It is demonstrated that HCV p7 derived from genotype 1a and 1b sequences are highly immunogenic in mice when employed as overlapping peptides formulated as nanoparticles with the cross-priming adjuvant, CAF09.

TL;DR: R reverse-genetics analysis of S1 (ACACUCCG, corresponding to miR-122 seed nucleotide positions 8-1), S2 (CACU CC, positions 7-2), and ACCC at the 5' end of the HCV genome found that 5'E mutations did not confer virus resistance to miravirsen treatment, and it was demonstrated that the5'E required four nucleotides for optimal function.

TL;DR: This study provides proof-of-concept for establishment of an efficient and economically attractive DSP with potential application for production of an inactivated whole virus vaccine against HCV for human use.

TL;DR: Persistent hepatitis C virus (HCV) infection affects 170 million people worldwide, and many infected individuals develop persistent infections that may lead to development of end-stage liver diseases, including liver cirrhosis and hepatocellular carcinoma.